PATHWAY BIOLOGIC, LLC – Trademark Portfolio
Entity Type: 16
PATHWAY BIOLOGIC, LLC holds 9 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 8 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 4 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include BIOHP and BIOPATH. The owner is based in PLANT CITY, FL.
111 E. TEVER STREET
PLANT CITY, FL 33563
Showing of trademarks Trademarks
Trademark Classifications
PATHWAY BIOLOGIC, LLC's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Scientific and technological services; industrial analysis and research services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does PATHWAY BIOLOGIC, LLC have?
PATHWAY BIOLOGIC, LLC has 9 U.S. trademarks filed with the USPTO. Of these, 2 registered, 1 abandoned, 6 cancelled.
What trademark classes does PATHWAY BIOLOGIC, LLC file in?
PATHWAY BIOLOGIC, LLC files trademarks across 4 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 42 (Computer & Scientific), Class 40 (Treatment & Processing), Class 5 (Pharmaceuticals). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are PATHWAY BIOLOGIC, LLC's most well-known trademarks?
PATHWAY BIOLOGIC, LLC's registered trademark portfolio includes well-known marks such as BIOHP and BIOPATH. These are among 2 currently registered trademarks in the portfolio.
What is PATHWAY BIOLOGIC, LLC's trademark registration success rate?
PATHWAY BIOLOGIC, LLC has a 22% trademark registration rate, with 2 out of 9 resolved applications resulting in successful registration. Currently, 0 applications are pending review.